ERBB2 and breast carcinoma: In patients with HER2‐low advanced breast cancer, trastuzumab deruxtecan (T‐Dxd) shows more encouraging efficacy (T‐Dxd group vs. TPC group: 9.9 vs. 5.1 months, HR: 0.50).8